keyword
MENU ▼
Read by QxMD icon Read
search

interferon therapy in hepatitis C

keyword
https://www.readbyqxmd.com/read/28647161/dot-c-a-cluster-randomised-feasibility-trial-evaluating-directly-observed-anti-hcv-therapy-in-a-population-receiving-opioid-substitute-therapy-from-community-pharmacy
#1
Andrew Radley, Jan Tait, John F Dillon
BACKGROUND: Direct-acting antiviral therapy (DAAs) for hepatitis C infection (HCV) have a much smaller burden of treatment than interferon-based regimes, require less monitoring and are very effective. New pathways are required to increase access to treatment amongst people prescribed opioid substitution therapy (OST). METHODS: An exploratory cluster randomised controlled trial with mixed methods evaluation was undertaken to compare the uptake of dried blood spot testing (DBST) and treatment of people with genotype 1 HCV infection in a conventional service pathway versus a pharmacist-led pathway in a population receiving OST...
June 21, 2017: International Journal on Drug Policy
https://www.readbyqxmd.com/read/28643457/eradication-of-hepatitis-c-virus-profoundly-prolongs-survival-in-hepatocellular-carcinoma-patients-receiving-transarterial-chemoembolization
#2
Wei Teng, Yi-Chung Hsieh, Kar-Wai Lui, Wei-Ting Chen, Chien-Fu Hung, Chien-Hao Huang, Yi-Cheng Chen, Wen-Juei Jeng, Chen-Chun Lin, Chun-Yen Lin, Shi-Ming Lin, I-Shyan Sheen
Adjuvant pegylated interferon plus ribavirin treatment (PegIFN/RBV) reduces recurrence and prolongs survival in early stage hepatocellular carcinoma (HCC) patients with chronic hepatitis C (CHC) infection receiving resection or ablation. However, the impact of antiviral therapy in intermediate and advanced stage of CHC-HCC patients is uncertain. This study aimed to investigate the impact PegIFN/RBV treatment on recurrence free interval and survival in HCC patients receiving transarterial chemoembolization (TACE) METHODS: From 2010 to 2013, 274 CHC patients from a 1073-patients based cohort composed of freshly diagnosed HCC and receiving TACE treatment the Chang Gung Memorial Hospital, Linkou Medical Center were recruited...
June 22, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28643451/polyclonal-and-monoclonal-b-lymphocytes-response-in-hcv-patients-treated-with-direct-acting-antiviral-agents
#3
Alvise Schiavinato, Alberto Zanetto, Giorgia Pantano, Francesca Tosato, Mitja Nabergoj, Paola Fogar, Elisa Piva, Martina Gambato, Enrica Franceschet, Annarosa Floreani, Fabio Farinati, Patrizia Burra, Francesco Paolo Russo, Mario Plebani
Hepatitis C Virus (HCV) chronic infection can be associated with extrahepatic manifestations such as mixed cryoglobulinemia and lymphoproliferative disorders that are endowed with increased rates of morbidity and all-cause mortality. In this study we used flow cytometry to evaluate the effect of Interferon-free antiviral treatment on peripheral blood lymphocytes in HCV patients with or without associated lymphoproliferative disorders. Flow cytometry analysis of peripheral blood lymphocytes were performed at baseline and at the end of treatment...
June 22, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28643404/occurrence-of-late-relapse-of-hepatitis-c-virus-confirmed-by-molecular-analysis-after-sustained-virological-response-to-interferon-ribavirin-based-therapy
#4
Kazuhiko Hayashi, Masatoshi Ishigami, Satoshi Yasuda, Yoji Ishizu, Teiji Kuzuya, Takashi Honda, Tetsuya Ishikawa, Yoshiki Hirooka, Hidemi Goto
BACKGROUND AND AIM: The optimal duration of follow-up for patients who achieve sustained virological responses (SVR) has become an important issue. Reports on long-term follow-up of SVR have demonstrated that 99% of patients maintained SVR. However, the limitations of a majority of studies include small patient numbers, short study periods, and lack of molecular analysis of hepatitis C virus (HCV) genome. The present study sought to evaluate the late relapse rate in long-term follow-up of patients who achieved SVR, with molecular analysis of HCV...
June 22, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/28641714/hepatitis-c-treatment-in-patients-with-porphyria-cutanea-tarda
#5
Ashwani K Singal, Krishna V R Venkata, Sarat Jampana, Fakhar-Ul Islam, Karl E Anderson
BACKGROUND: Hepatitis C virus (HCV) infection is a common susceptibility factor for porphyria cutanea tarda (PCT). Experience on HCV treatment in patients with PCT is limited. Recently, HCV treatment has improved with direct-acting antivirals (DAA). We review our experience on HCV treatment in patients with PCT with older and newer regimens. MATERIALS AND METHODS: A retrospective chart review was conducted. HCV treatment was attempted 22 times in 13 patients with PCT (5 attempts in 1, 2 in 5 and 1 in the other 7 patients)...
June 2017: American Journal of the Medical Sciences
https://www.readbyqxmd.com/read/28638221/prevalence-of-ifnl3-rs4803217-single-nucleotide-polymorphism-and-clinical-course-of-chronic-hepatitis-c
#6
Bogna Świątek-Kościelna, Ewelina Kałużna, Ewa Strauss, Jerzy Nowak, Iwona Bereszyńska, Ewelina Gowin, Jacek Wysocki, Jolanta Rembowska, Dominika Barcińska, Iwona Mozer-Lisewska, Danuta Januszkiewicz-Lewandowska
AIM: To evaluate the association of IFNL3 (IL28B) SNP rs4803217 with severity of disease and treatment outcome in chronic hepatitis C (CHC). METHODS: The study enrolled 196 CHC Polish patients (82 women and 114 men in age 20-64) infected with hepatitis C virus (HCV) genotype 1. They were treatment naïve and qualified to pegylated interferon alpha (PEG-IFN-α) and ribavirin (RBV) therapy. The analyzed baseline parameters included: degree of inflammation, stage of fibrosis, viral load as well as alanine aminotransferase (ALT), asparagine aminotransferase (AST) and total bilirubin (TBIL)...
June 7, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28634198/the-effect-of-sustained-virological-response-on-the-risk-of-extrahepatic-manifestations-of-hepatitis-c-virus-infection
#7
Parag Mahale, Eric A Engels, Ruosha Li, Harrys A Torres, Lu-Yu Hwang, Eric L Brown, Jennifer R Kramer
BACKGROUND AND AIM: Chronic HCV infection is associated with several extrahepatic manifestations (EHMs). Data on the effect of sustained virological response (SVR) on the risk of EHMs are limited. METHODS: We conducted a retrospective cohort study using data of patients from the US Veterans Affairs HCV Clinical Case Registry who had a positive HCV RNA test (10/1999-08/2009). Patients receiving interferon-based antiviral therapy (AVT) were identified. SVR was defined as negative HCV RNA at least 12 weeks after end of AVT...
June 20, 2017: Gut
https://www.readbyqxmd.com/read/28632923/comparing-the-risk-of-hepatitis-b-virus-reactivation-between-direct-acting-antiviral-therapies-and-interferon-based-therapies-for-hepatitis-c
#8
Naoki Kawagishi, Goki Suda, Masahiro Onozawa, Megumi Kimura, Osamu Maehara, Masatsugu Ohara, Takaaki Izumi, Machiko Umemura, Jun Ito, Masato Nakai, Takuya Sho, Mitsuteru Natsuizka, Kenichi Morikawa, Koji Ogawa, Naoya Sakamoto
BACKGROUND: Hepatitis B virus (HBV)-reactivation has been reported during anti-hepatitis C treatment in patients with hepatitis C virus (HCV) and HBV co-infection. We aimed to evaluate the frequency and risk factors of HBV-reactivation during anti-HCV therapy and compared those between interferon (IFN)-free direct-acting antiviral (DAA)-therapies and IFN-based therapies. METHODS: 322 patients with HCV infection receiving anti-HCV therapy were retrospectively screened...
June 20, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28629242/differential-effect-of-p38-and-mk2-kinase-inhibitors-on-the-inflammatory-and-toxicity-biomarkers-in-vitro
#9
R K Singh, M Diwan, S G Dastidar, A K Najmi
BACKGROUND: Many inflammatory responses including chemotaxis, production of nitric oxide, and modulation of pro-inflammatory cytokines in immunological cells are mediated by p38MAPK. Due to its pivotal role, p38MAPK has been extensively explored as a molecular target for inhibition of chronic inflammation; however, it has not been successful so far due to serious toxicity issues. Among several downstream substrates of p38, mitogen-activated protein kinase-activated protein kinase 2 (MK2) has been reported to be a direct and essential downstream component in regulation of innate immune and inflammatory responses...
January 1, 2017: Human & Experimental Toxicology
https://www.readbyqxmd.com/read/28628931/-the-probabilistic-efficiency-frontier-a-value-assessment-of-treatment-options-in-hepatitis-c
#10
Axel C Mühlbacher, Andrew Sadler
Background The German Institute for Quality and Efficiency in Health Care (IQWiG) recommends the concept of the efficiency frontier to assess health care interventions. The efficiency frontier supports regulatory decisions on reimbursement prices for the appropriate allocation of health care resources. Until today this cost-benefit assessment framework has only been applied on the basis of individual patient-relevant endpoints. This contradicts the reality of a multi-dimensional patient benefit. Objective The objective of this study was to illustrate the operationalization of multi-dimensional benefit considering the uncertainty in clinical effects and preference data in order to calculate the efficiency of different treatment options for hepatitis C (HCV)...
June 19, 2017: Das Gesundheitswesen
https://www.readbyqxmd.com/read/28627791/no-evidence-of-hepatitis-b-virus-reactivation-in-patients-with-resolved-infection-treated-with-direct-acting-antivirals-for-hepatitis-c-in-a-large-real-world-cohort
#11
V T Mücke, M M Mücke, K-H Peiffer, N Weiler, T M Welzel, C Sarrazin, S Zeuzem, A Berger, J Vermehren
BACKGROUND: Hepatitis B virus (HBV) reactivation has been observed following interferon (IFN)-based treatment in HBV/hepatitis C virus (HCV) co-infected patients. Recent reports suggest that reactivation may also occur in both hepatitis B surface antigen (HBsAg)-positive and HBsAg-negative patients during HCV treatment with direct-acting antivirals (DAAs). AIM: To investigate the rate of patients with HBV reactivation during IFN-based and IFN-free HCV treatment in a large real-world cohort...
June 19, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28627363/effect-of-interferon-based-and-free-therapy-on-early-occurrence-and-recurrence-of-hepatocellular-carcinoma-in-chronic-hepatitis-c
#12
Hiroko Nagata, Mina Nakagawa, Yasuhiro Asahina, Ayako Sato, Yu Asano, Tomoyuki Tsunoda, Masato Miyoshi, Shun Kaneko, Satoshi Otani, Fukiko Kawai-Kitahata, Miyako Murakawa, Sayuri Nitta, Yasuhiro Itsui, Seishin Azuma, Sei Kakinuma, Toshihiko Nouchi, Hideki Sakai, Makoto Tomita, Mamoru Watanabe
BACKGROUND AND AIMS: Although treatment for hepatitis C virus has dramatically improved by the development of direct-acting antiviral agents (DAAs), whether interferon (IFN)-free therapy reduces hepatocarcinogenesis in an equivalent manner to IFN-based therapy remains controversial. The aims of this study were to evaluate the occurrence and recurrence of hepatocellular carcinoma (HCC) in chronic hepatitis C (CHC) patients treated with DAAs and to identify biomarkers of HCC development after antiviral treatment...
June 13, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/28626376/successful-treatment-for-chronic-hepatitis-c-autoimmune-hepatitis-overlap-syndrome-due-to-daclatasvir-and-asunaprevir
#13
Ayumi Sugiura, Shuichi Wada, Hiromitsu Mori, Takefumi Kimura, Yoshiaki Matsuda, Naoki Tanaka, Eiji Tanaka, Kendo Kiyosawa
Persistent hepatitis C virus (HCV) infection may induce autoimmune diseases and chronic hepatitis C is sometimes accompanied by autoimmune hepatitis (AIH). However, we are worried about the treatment for chronic hepatitis C-AIH overlap syndrome because interferon-based antiviral therapies may enhance autoimmunity and immunosuppressive corticosteroid administration may promote viral replication. Here, we report a patient having chronic hepatitis C-AIH overlap syndrome treated with the direct-acting antivirals (DAA), daclatasvir and asunaprevir...
May 2017: Case Reports in Gastroenterology
https://www.readbyqxmd.com/read/28624134/efficacy-of-response-guided-directly-observed-pegylated-interferon-and-self-administered-ribavirin-for-people-who-inject-drugs-with-hepatitis-c-virus-genotype-2-3-infection-the-activate-study
#14
Jason Grebely, Olav Dalgard, Evan B Cunningham, Behzad Hajarizadeh, Graham R Foster, Philip Bruggmann, Brian Conway, Markus Backmund, Geert Robaeys, Tracy Swan, Janaki Amin, Philippa S Marks, Sophie Quiene, Tanya L Applegate, Martin Weltman, David Shaw, Adrian Dunlop, Margaret Hellard, Julie Bruneau, Håvard Midgard, Stefan Bourgeois, Cornelia Staehelin, Gregory J Dore
BACKGROUND: There are few data on treatment for hepatitis C virus (HCV) infection among people with ongoing injecting drug use. This study evaluated the efficacy of response-guided therapy for chronic HCV genotypes 2/3 infection among people with ongoing injecting drug use or receiving opioid substitution therapy (OST). A secondary aim was to identify predictors of HCV treatment response. METHODS: ACTIVATE was a multicentre clinical trial recruited between 2012 and 2014...
June 14, 2017: International Journal on Drug Policy
https://www.readbyqxmd.com/read/28624110/interferon-free-antiviral-therapy-for-chronic-hepatitis-c-among-patients-in-the-liver-transplant-setting
#15
REVIEW
Marjolein van Tilborg, Raoel Maan, Adriaan J van der Meer, Robert J de Knegt
Chronic hepatitis C (HCV) infection remains a major public health problem with many infected individuals worldwide. The revolutionary discovery of highly effective direct-acting antivirals (DAAs) makes chronic HCV infection a curable disease, even in patients with advanced liver disease. Liver function may improve shortly after initiation of antiviral therapy in patients on the waiting list and could even obviate the need for transplantation. However, whether these short term benefits also result in a favorable prognosis on the long-term remains to be seen and this fuels the discussion whether DAAs should be used prior to liver transplantation in all patients...
April 2017: Best Practice & Research. Clinical Gastroenterology
https://www.readbyqxmd.com/read/28617830/on-treatment-decrease-of-nkg2d-correlates-to-early-emergence-of-clinically-evident-hepatocellular-carcinoma-after-interferon-free-therapy-for-chronic-hepatitis-c
#16
Po-Sung Chu, Nobuhiro Nakamoto, Nobuhito Taniki, Keisuke Ojiro, Takeru Amiya, Yuko Makita, Hiroko Murata, Akihiro Yamaguchi, Shunsuke Shiba, Rei Miyake, Tadashi Katayama, Aya Ugamura, Akihiko Ikura, Karin Takeda, Hirotoshi Ebinuma, Hidetsugu Saito, Takanori Kanai
BACKGROUND AND AIMS: Interferon (IFN)- free direct antiviral agents (DAAs) with rapid HCV eradication might evoke immunological reconstitutions, and some early recurrences of HCC after IFN-free DAAs have been reported. This study aimed to investigate whether natural killer group 2, member D (NKG2D) predicts early emergence of HCC after IFN-free DAAs. METHODS: We conducted a clinical practice-based observational study of 101 patients infected with genotype 1 HCV who received IFN-free (DAAs), and stratified them into those who did or did not develop early (i...
2017: PloS One
https://www.readbyqxmd.com/read/28614914/ip-10-expression-in-patients-with-chronic-hbv-infection-and-its-ability-to-predict-the-decrease-in-hbsag-levels-after-treatment-with-entecavir
#17
Kai Zhao, Tao Yang, Mimi Sun, Wei Zhang, Yong An, Gang Chen, Lei Jin, Qinghua Shang, Wengang Song
Interferon-γ-inducible protein 10 (IP-10), also known as chemokine C-X-C motif ligand (CXCL) 10, is closely associated with antiviral immunity and the progression of chronic hepatitis B (CHB). However, the value of baseline serological and histological IP-10 expression levels in predicting the efficacy of the antiviral response to nucleoside/nucleotide analogues (NAs) is still unknown. In our research, intrahepatic and peripheral IP-10 expression levels were systemically examined before and after treatment with entecavir (ETV)...
June 14, 2017: Molecules and Cells
https://www.readbyqxmd.com/read/28614389/immunological-dynamics-associated-with-rapid-virological-response-during-the-early-phase-of-type-i-interferon-therapy-in-patients-with-chronic-hepatitis-c
#18
Jae-Won Lee, Won Kim, Eun-Kyung Kwon, Yuri Kim, Hyun Mu Shin, Dong-Hyun Kim, Chan-Ki Min, Ji-Yeob Choi, Won-Woo Lee, Myung-Sik Choi, Byeong Gwan Kim, Nam-Hyuk Cho
Type I interferons (IFNs) play an important role in antiviral immunity as well as immunopathogenesis of diverse chronic viral infections. However, the precise mechanisms regulating the multifaceted effects of type I IFNs on the immune system and pathological inflammation still remain unclear. In order to assess the immunological dynamics associated with rapid viral clearance in chronic hepatitis C patients during the acute phase of type I IFN therapy, we analyzed multiple parameters of virological and immunological responses in a cohort of 59 Korean hepatitis C patients who received pegylated IFN-α and ribavirin (IFN/RBV)...
2017: PloS One
https://www.readbyqxmd.com/read/28611343/hbsag-clearance-in-chronic-hepatitis-b-patients-with-add-on-pegylated-interferon-alfa-2a-to-ongoing-tenofovir-treatment-a-randomized-controlled-study
#19
Hamad Al Ashgar, Musthafa C Peedikayil, Mohammed Al Quaiz, Fahad Al Sohaibani, Abdulrahman Al Fadda, Mohammed Q Khan, Einar Thoralsson, Sahar Al Thawadi, Ahmed Al Jedai, Khalid Al Kahtani
BACKGROUND/AIMS: The ideal end point of treatment for chronic hepatitis B virus (HBV) infection is sustained off-therapy hepatitis B surface antigen (HBsAg) loss with or even without seroconversion to anti-HBs. We investigated the role of adding PEGylated interferon (PEG IFN) to ongoing tenofovir treatment in chronic HBV patients for achieving HBsAg clearance. PATIENTS AND METHODS: In this randomized controlled trial, chronic HBV patients who have been receiving tenofovir for >6 months with HBV viral load <2000 IU/ml were randomized into two groups...
May 2017: Saudi Journal of Gastroenterology: Official Journal of the Saudi Gastroenterology Association
https://www.readbyqxmd.com/read/28610605/adherence-to-response-guided-pegylated-interferon-and-ribavirin-for-people-who-inject-drugs-with-hepatitis-c-virus-genotype-2-3-infection-the-activate-study
#20
Evan B Cunningham, Behzad Hajarizadeh, Olav Dalgard, Janaki Amin, Margaret Hellard, Graham R Foster, Philip Bruggmann, Brian Conway, Markus Backmund, Geert Robaeys, Tracy Swan, Philippa S Marks, Sophie Quiene, Tanya L Applegate, Martin Weltman, David Shaw, Adrian Dunlop, Julie Bruneau, Håvard Midgard, Stefan Bourgeois, Maria Christine Thurnheer, Gregory J Dore, Jason Grebely
BACKGROUND: The aims of this analysis were to investigate treatment completion and adherence among people with ongoing injecting drug use or receiving opioid substitution therapy (OST) in a study of response-guided therapy for chronic HCV genotypes 2/3 infection. METHODS: ACTIVATE was a multicenter clinical trial recruited between 2012 and 2014. Participants with genotypes 2/3 were treated with directly observed peg-interferon alfa-2b (PEG-IFN) and self-administered ribavirin for 12 (undetectable HCV RNA at week 4) or 24 weeks (detectable HCV RNA at week 4)...
June 13, 2017: BMC Infectious Diseases
keyword
keyword
58041
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"